Clinical Trial Update: Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. [Phase 3]

View source ↗

Summary

Phase 3 trial in pediatric and adolescent patients with active systemic juvenile idiopathic arthritis comparing oral upadacitinib with subcutaneous/intravenous …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Tocilizumab (tocilizumab)
• Upadacitinib (upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Juvenile Idiopathic Arthritis | Phase 3 | Status: RECRUITING